首页> 外文期刊>European Journal of Pharmacology: An International Journal >Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice.
【24h】

Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice.

机译:Rho激酶抑制剂Y-27632和法舒地尔对糖尿病小鼠海绵体的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Relaxant responses to two Rho-kinase inhibitors, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate (Y-27632) and fasudil, were compared in the corpus cavernosum obtained from diabetic and non-diabetic mice. Streptozotocin (100 mg kg(-1) day(-1), for 2 days) induced diabetes with a blood glucose level of 318+/-55.4 mg dl(-1); whereas it was 85.4+/-4.1 mg dl(-1) in control mice (P<0.05). Electrical field stimulation (40 V, 0.5 ms, 1, 2, 4, 8, 16 Hz for 15 s) and acetylcholine-induced relaxations were markedly attenuated in the corpus cavernosum from streptozotocin-diabetic mice whereas responses to Y-27632 (10(-9)-3 x 10(-5) M) and fasudil (10(-9)-3 x 10(-5) M) were not altered. EC(50) values for Y-27632 were 2.98+/-0.89 and 4.19+/-2.71 microM in the corpus cavernosum from control and diabetic mice, respectively (P>0.05). The values for fasudil were 7.42+/-4.91 and 3.53+/-1.41 microM in the corpus cavernosum from control and diabetic mice, respectively (P>0.05). These results may suggest that, in diabetes, the relaxant effects of the Rho-kinase inhibitors may not be changed and thus, they may have a beneficial therapeutic effect in diabetic erectile dysfunction.
机译:在语料库中比较了对两种Rho激酶抑制剂(+)-(R)-反式-4-(1-氨基乙基)-N-(4-吡啶基)环己烷甲酰胺二盐酸盐(Y-27632)和法舒地尔的松弛反应从糖尿病和非糖尿病小鼠获得的海绵体。链脲佐菌素(100 mg kg(-1)天(-1),持续2天)诱发糖尿病,血糖水平为318 +/- 55.4 mg dl(-1);而对照小鼠为85.4 +/- 4.1 mg dl(-1)(P <0.05)。链脲佐菌素-糖尿病小鼠的海绵体中的电场刺激(40 V,0.5 ms,1、2、4、8、16 Hz持续15 s)和乙酰胆碱引起的松弛明显减弱,而对Y-27632的反应(10( -9)-3 x 10(-5)M)和法舒地尔(10(-9)-3 x 10(-5)M)没有改变。来自对照组和糖尿病小鼠的海绵体中Y-27632的EC(50)值分别为2.98 +/- 0.89和4.19 +/- 2.71 microM(P> 0.05)。来自对照组和糖尿病小鼠的海绵体中法舒地尔的值分别为7.42 +/- 4.91和3.53 +/- 1.41 microM(P> 0.05)。这些结果表明,在糖尿病中,Rho激酶抑制剂的松弛作用可能不会改变,因此,它们在糖尿病性勃起功能障碍中可能具有有益的治疗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号